As a specific COX‐2 inhibitor approved by FDA, celecoxib reportedly reverses PGE2‐mediated CSCs expansion[[qv: 2b,3b,13]] and metastasis,[[qv: 6c,7]] and dampens P‐gp‐dependent drug resistance induced by chemotherapy,[[qv: 2b,3b,10a,11b,14]] thereby presumably suppressing cancer repopulation. This evidence concerns the gene PGP and cancer.